Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-05-08
2007-05-08
Campell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007100, C435S007900, C436S064000, C530S350000
Reexamination Certificate
active
11017119
ABSTRACT:
The present invention is directed to diagnostic methods based upon the expression of the protein prostasin. In particular, it is concerned with assays performed on women to determine their risk of ovarian cancer.
REFERENCES:
patent: 5604106 (1997-02-01), Liotta et al.
patent: 5695761 (1997-12-01), Denhardt et al.
patent: 5712104 (1998-01-01), Yamamoto
patent: 5801004 (1998-09-01), Hudson et al.
patent: 5866119 (1999-02-01), Bandman et al.
patent: 5928883 (1999-07-01), Gleich et al.
patent: 6414219 (2002-07-01), Denhardt et al.
patent: 6675104 (2004-01-01), Paulse et al.
patent: 6686444 (2004-02-01), Ashkar
patent: 2002/0039753 (2002-04-01), Chai et al.
patent: 2002/0052308 (2002-05-01), Rosen et al.
patent: 2003/0087250 (2003-05-01), Monahan et al.
Brown et al., “Osteopontin expression and distribution in human carcinomas,” American Journal of Pathology, vol. 145 No. 3, pp. 610-623 (Sep. 1994).
Brown et al., “Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces,” Molecular Biology of the Cell, vol. 3 No. 10. Pages 1169-1180 (Oct. 1992).
Tiniakos et al., “Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP),” Human Pathology, vol. 29 No. 11, pp. 1250-1254 (Nov. 1998).
Zhong et al., “Evaluation of MUC1 and EGP40 in bone marrow and peripheral blood as a marker for occult breast cancer,” Archives of Gynecology and Obstetrics, vol. 164 No. 4, pp. 177-181 (Jan. 2001).
Ali, et al., “Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and Regulated on Activation Normal T Cell Expressed and Secreted Are Expressed by Human Breast Carcinoma Cells and Support Eosinophil and Activation,”Am. J. Path. 157:313-321 (2000).
Alper, “Turning Sweet on Cancer,”Science 301:159-160 (2003).
Barker, et al., “Eosinophil Cationic Protein cDNA, Comparison with Other Toxic Cationic Proteins and Rebonucleases,”J. Immunol. 143:952-955 (1989).
Bast, et al., “A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer,”N. Engl. J. Med. 309:883-887 (1983).
Beintema, et al., “Amino Acid Sequence of the Nonsecretory Ribonuclease of Human Urine,”Biochemistry 27:4530-4538 (1988).
Berteau, et al., “Prostasin mRNA to Detect Prostate Cells in Blood of Cancer Patients,”Clin. Chem. Lab. Med. 37:S119 (1999).
Blumenthal, et al., “Degranulating Eosinophils in Human Endometriosis,”Am. J. Path. 156:1581-1588 (2000).
Chen, et al., “Down-Regulation of Prostasin Serine Protease: A Potential Invasion Suppressor in Prostate Cancer,”Prostate 48:93-103 (2001).
Chen, et al., “Prostasin Serine Protease Inhibits Breast Cancer Invasiveness and Is Transcriptionally Regulated by Promoter DNA Methylation,”Int. J. Cancer 97:323-329 (2002).
Cheung, et al., “Identify Metastasis-Associated Genes in Hepatocellular Carcinoma through Clonality Delineation for Multinodular Tumor,”Cancer Res. 62:4711-4721 (2002).
Coolen, et al., “Elevation of Brain-Type Creatine Kinase in Serum from Patients with Carcinoma,”Cancer 44:1414-1418 (1979).
Cramer, et al., “Carotenoids, Antioxidants and Ovarian Cancer Risk in Pre- and Postmenopausal Women,”Int. J. Cancer 94:128-134 (2001).
Daly, et al., “The Search for Predictive Patterns in Ovarian Cancer: Proteomics Meets Bioinformatics,”Cancer Cell 1:111-112 (2002).
Denhardt, et al., “Osteopontin: A Protein with Diverse Functions,”FASEB J. 7:1475-1482 (1993).
DeRisi, et al., “Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer,”Nature Genetics 14:457-460 (1996).
Dorta, et al., “Tumour-Associated Tissue Eosinophilia as a Prognostic Factor in Oral Squamous Cell Carcinomas,”Histopathology 41:152-157 (2002).
Fernández-Aceñero, et al., “Prognostic Influence of Tumor-Associated Eosinophilic Infiltrate in Colorectal Carcinoma,”Cancer 88:1544-1548 (2000).
Fish, et al., “Changes in Serum Acute Phase Proteins in Ovarian Cancer Patients Receiving Cis-Diamminedichloroplatinum (CDDP) Infusion Therapy,”Clinical Biochem. 17:39-41 (1984).
Fish, et al., “Serum Haptoglobin and α1-Acid Glycoprotein as Indicators of the Effectiveness ofcis-Diamminedichloroplatinum (CDDP) in Ovarian Cancer Patients—a Preliminary Report,”Eur. J. Cancer Clin. Oncol. 20:625-630 (1984).
Giachelli, et al., “Molecular and Cellular Biology of Osteopontin,”Trends Cardiovasc. Med. 5:88-95 (1995).
Gingrich, et al., “Metastatic Prostate Cancer in a Transgenic Mouse,”Cancer Res. 56:4096-4102 (1996).
Hakomori, “Glycosylation Defining Cancer Malignancy: New Wine in an Old Bottle,”Proc. Natl. Acad. Sci. USA 99:10231-10233 (2002).
Hamann, et al., “Sequence of Human Eosinophil-Derived Neurotoxin cDNA: Identity of Deduced Amino Acid Sequence with Human Nonsecretory Ribonucleases,”Gene 83:161-167 (1989).
Hamann, et al., “Stucture and Chromosome Localization of the Human Eosinophil-Derived Neurotozin and Eosinophil Cationic Protein Genes: Evidence for Intronless Coding Sequences in the Ribonuclease Gene Superfamily,”Genomics 7:535-546 (1990).
Harvey, et al., “Cancer Cells Release a Covalent Complex Containing Disulfide-Linked Domains from Urinary Plasminogen Activator, Neural Cell Adhesion Molecule, and Haptoglobin α and β Chains,”Arch. Biochem. Biophys. 345:289-298 (1997).
Heid, et al., “Real Time Quantitative PCR,”Genome Res. 6:986-994 (1996).
Hooper, et al., “Testisin, a New Human Serine Proteinase Expressed by Premeiotic Testicular Germ Cells and Lost in Testicular Germ Cell Tumors,”Cancer Res. 59:3199-3205 (1999).
Hooper, et al., “Localization, Expression and Genomic Structure of the Gene Encoding the Human Serine Protease Testisin,”Biochimica et Biophysica Acta 1492:63-71 (2000).
Kakugawa, et al., “Up-Regulation of Plasma Membrane-Associated Ganglioside Sialidase (Neu3) in Human Colon Cancer and Its Involvement in Apoptosis Suppression,”Proc. Natl. Acad. Sci USA 99:10718-10723 (2002).
Kibel, et al., “Loss of Heterozygosity at 12P12-13 in Primary and Metastatic Prostate Adenocarcinoma,”J. Urol. 164:192-196 (2000).
Kiefer, et al., “The cDNA and Derived Amino Acid Sequence for Human Osteopontin,”Nuc. Ac. Res. 17:3306 (1989).
Kim, et al., “Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer,”JAMA 287:1671-1679 (2002).
Ko, et al., “Haptoglobin Typing and Quantitation in Normal Chinese Females and Gynecologic Cancer Patients,”Chinese J. Microbiol. Immunol. 13:149-157 (1980).
Ko, et al., “Haptoglobin Typing and Quantitation in Normal Chinese Females and Gynecologic Cancer Patients,”Chinese J. Microbiol. Immunol. 13:149-157 (1980) Abstract; Database Medline, Accession No. 81089629.
Kodama, et al., “Large Cell Carcinoma of the Lung Associated with Marked Eosinophilia,”Cancer 54:2313-2317 (1984).
Kurtz, et al., “Serum Creatine Kinase BB Isoenzyme as a Diagnostic Aid in Occult Small Cell Lung Cancer,”Cancer 56:562-566 (1985).
Mills, et al., “Future for Ovarian Cancer Screening: Novel Markers From Emerging Technologies of Transcriptional Profiling and Proteomics,”J. Natl. Cancer. Inst. 93:1437-1439 (2001).
Mok, et al., “Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology,”J. Natl. Cancer Inst. 93:1458-1464 (2001).
Mok, et al., “Molecular Cloning of Differentially Expressed Genes in Human Epithelial Ovarian Cancer,”Gynecologic Oncol. 52:247-252 (1994).
Mok, et al., “SPARC, an Extracellular Matrix Protein with Tumor-Suppressing Activity in Human Ovarian Epithelial Cells,”Oncogene 12:1895-1901 (19
Mok Samuel C.
Wong Kwong-Kwok
Battelle (Memorial Institute)
Campell Bruce R.
Law Office of Michael A. Sanzo, LLC
Lucas Zachariah
The Brigham and Women's Hospital, Inc.
LandOfFree
Methods of detecting cancer based on osteopontin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of detecting cancer based on osteopontin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of detecting cancer based on osteopontin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3784793